BiotechTubeBiotechTube
Home/Rigel Pharmaceuticals/Michael P. Miller
MP

Michael P. Miller

Member of the Board of Directors (Appointed Feb 2026)

Rigel Pharmaceuticals

Therapeutic Areas

HematologyOncologyImmunology

Rigel Pharmaceuticals Pipeline

DrugIndicationPhase
TAVALISSE (fostamatinib disodium hexahydrate)Chronic Immune Thrombocytopenia (ITP) in adultsApproved
TAVALISSEHospitalized patients with COVID-19Emergency Use Authorization
REZLIDHIA (olutasidenib)Relapsed or Refractory Acute Myeloid Leukemia (AML) with susceptible IDH1 mutationApproved
GAVRETO (pralsetinib)RET-altered cancers (e.g., NSCLC, thyroid cancer)Approved
IRAK1/4 InhibitorLower-Risk Myelodysplastic Syndrome (LR-MDS)Phase 1b
RIPK1 InhibitorImmunological DiseasesPreclinical

Leadership Team at Rigel Pharmaceuticals

RR
Raul R. Rodriguez
President and Chief Executive Officer
DS
Dean Schorno
Executive Vice President and Chief Financial Officer
DA
David A. Santos
Executive Vice President and Chief Commercial Officer
LR
Lisa Rojkjaer
Executive Vice President and Chief Medical Officer
RJ
Raymond J. Furey
Executive Vice President, General Counsel and Corporate Secretary
JL
Joseph Lasaga
Executive Vice President and Chief Business Officer
JP
Julie Patel
Senior Vice President, Human Resources
KA
Kamil Ali-Jackson
Member of the Board of Directors
MW
Mark W. Frohlich
Member of the Board of Directors
View full Rigel Pharmaceuticals profile